Alternatives to Degron Therapeutics

Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.

AI safety and research company building reliable, interpretable, and steerable AI systems.

Personalizing cancer care through a novel, physics-informed approach to predict tumor response to therapy.

Immunotherapy company targeting oncology and autoimmune diseases.

Advancing next-generation mRNA medicines.

Clinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.

Developing highly targeted, small molecule medicines.

A biotechnology company focused on oncology drug discovery.

Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.

Enzyme-based technology to break down alcohol in the stomach.

A vertically-integrated procurement platform for the life sciences industry.

Clinical-stage biopharmaceutical company developing next-generation therapies for obesity and cardiometabolic diseases.

Biopharmaceutical company developing and commercializing CNS disease treatments.

A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.

Clinical-stage biopharmaceutical company leveraging a proprietary platform to discover and develop novel precision medicines from fungi.

A global leader in clinical pharmacology and bioanalytical sciences.

Freenome is a biotechnology company developing a multi-cancer early detection blood test using machine learning and biology.

Biopharmaceutical company developing novel small-molecule therapeutics for rare kidney diseases, particularly Autosomal Dominant Polycystic Kidney Disease (ADPKD).

A biotechnology company developing genetic therapies for rare disorders.

Biotechnology company developing novel therapeutics by harnessing the autophagy pathway to treat serious diseases.

A clinical-stage biopharmaceutical company developing novel immunotherapies.

A full-stack spatial biology company.

A clinical-stage biopharmaceutical company developing novel therapies for neurological disorders.

Developing gene editing therapies to lower cholesterol.

Developing novel immunotherapies and diagnostics for cancer.

Clinical-stage biopharmaceutical company developing novel treatments for exocrine pancreatic insufficiency.

Biotechnology company advancing novel therapeutics using its proprietary LEADS drug discovery platform.

A University of Cambridge spin-out tackling unmet drug screening needs by combining materials engineering and cell biology.

Engineering scalable gene therapies for broader patient populations.

A biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension.

The first Integrated Development and Manufacturing Organization (IDMO) for cell therapies.

Biotechnology company developing next-generation gene therapies using a proprietary protein splicing platform.

Platform designed to cut cell and gene therapy production costs.

A biopharmaceutical company focused on developing and commercializing therapies for rare diseases.

Pioneering vision restoration therapies for severe retinal degenerations.

Advancing deupirfenidone as a potential new standard of care for Idiopathic Pulmonary Fibrosis (IPF).

An end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials, focusing on lung and heart disease.

Advancing clinical stage pipeline targeting new and major neurology and neuropsychiatric disorders.

Developing ultrasound-mediated nonviral genetic medicines.

AI-native biotech company designing next-generation CAR T therapies for solid tumors.

A biotechnology ecosystem company powering the future of drug discovery and development through AI-driven platforms and integrated services.

Developing novel therapies to reverse aging and extend lifespan.

A biotechnology company developing gene therapy treatments for rare, debilitating genetic diseases.

Developing Quantum ADCs against the tumor microenvironment for innovative cancer therapies.

A clinical-stage biopharmaceutical company developing novel cell therapies for AL Amyloidosis and other serious diseases.

Provides regulated, secure, and high-yield digital asset solutions for institutional and corporate treasuries.

Developing microbiome-based therapeutics to address underlying disease biology, particularly in gastrointestinal health.

A commercial-stage immunotherapy company developing novel treatments for cancer and infectious diseases.

A biotechnology company focused on developing novel enzyme-based therapies for reflux disease.

Developing epigenetic reprogramming drugs for age restoration.

AI platform for engineering molecular glues to create a new class of medicines.

Developing first-in-class oral therapy for BK polyomavirus infections.

Clinical-stage pharmaceutical company developing innovative oral therapies for diabetes and metabolic disorders.

Developing and manufacturing laminin-based cell culture substrates for advanced cell therapies and drug discovery.

Advancing scalable microbiome-based therapeutics for severe and chronic diseases.

Scalable, one-time curative in-vivo gene editing therapies.

A biopharmaceutical company developing RNA interference (RNAi)-based medicines.

Clinical-stage biopharmaceutical company developing transformative, best-in-class neuropsychiatric therapies.

Developing novel male contraceptives.